TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582)
- PMID: 33963815
- DOI: 10.1002/adhm.202100030
TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582)
Abstract
Although mesenchymal stem cells (MSCs) can be engineered to deliver the TNF-related apoptosis-inducing ligand (TRAIL) as an effective anticancer therapy, the clinical application is hampered by the costly manufacturing of therapeutic MSCs. Therefore, it is needed to find an alternative cell-free therapy. In this study, TRAIL-armed endoplasmic reticulum (ER)-derived nanosomes (ERN-T) are successfully prepared with an average size of 70.6 nm in diameter from TRAIL transduced MSCs. It is demonstrated that the ERN-T is significantly more efficient for cancer cell killing than the soluble recombinant TRAIL (rTRAIL). AZD5582 is an antagonist of the inhibitors of apoptosis proteins (IAPs), and its combination with ERN-T induces strikingly enhanced apoptosis in cancerous but not normal cells. AZD5582 sensitizes resistant cancer cells to TRAIL through concomitant downregulation of IAP members like XIAP and the Bcl2 family member Mcl-1. Intravenously infused ERN-Ts accumulate in tumors for over 48 h indicating good tumor tropism and retention. The combination of ERN-T and AZD5582 drastically promotes therapeutic efficacy comparing with the cotreatment by rTRAIL and AZD5582 in a subcutaneous MDA-MB-231 xenograft tumor model. The data thus demonstrate that ERN-T can be a novel cell-free alternative to TRAIL-expressing MSC-based anticancer therapy and its efficacy can be drastically enhanced through combination with AZD5582.
Keywords: AZD5582; ER nanosomes; MSC; TRAIL; cancer resistance.
© 2021 Wiley-VCH GmbH.
Similar articles
-
Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.Acta Histochem. 2022 Feb;124(2):151856. doi: 10.1016/j.acthis.2022.151856. Epub 2022 Jan 22. Acta Histochem. 2022. PMID: 35077998
-
EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.J Mol Med (Berl). 2022 Apr;100(4):629-643. doi: 10.1007/s00109-022-02180-9. Epub 2022 Mar 5. J Mol Med (Berl). 2022. PMID: 35247069
-
A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.Oncotarget. 2015 Sep 29;6(29):26895-908. doi: 10.18632/oncotarget.4822. Oncotarget. 2015. PMID: 26314849 Free PMC article.
-
Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.Int J Mol Sci. 2018 Jul 27;19(8):2188. doi: 10.3390/ijms19082188. Int J Mol Sci. 2018. PMID: 30060445 Free PMC article. Review.
-
Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.J Cell Physiol. 2018 Oct;233(10):6470-6485. doi: 10.1002/jcp.26585. Epub 2018 May 9. J Cell Physiol. 2018. PMID: 29741767 Review.
Cited by
-
Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway.Apoptosis. 2023 Aug;28(7-8):1060-1075. doi: 10.1007/s10495-023-01842-4. Epub 2023 Apr 15. Apoptosis. 2023. PMID: 37060507
-
Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.Cancer Sci. 2024 Mar;115(3):820-835. doi: 10.1111/cas.16059. Epub 2023 Dec 27. Cancer Sci. 2024. PMID: 38151993 Free PMC article.
-
Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy.Cancers (Basel). 2022 Jul 21;14(14):3550. doi: 10.3390/cancers14143550. Cancers (Basel). 2022. PMID: 35884614 Free PMC article.
References
-
- S. R. Wiley, K. Schooley, P. J. Smolak, W. S. Din, C.-P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, R. G. Goodwin, Immunity 1995, 3, 673.
-
- G. E. Naoum, D. J. Buchsbaum, F. Tawadros, A. Farooqi, W. O. Arafat, Oncol. Rev. 2017, 11, 332.
-
- L. Y. Dimberg, C. K. Anderson, R. Camidge, K. Behbakht, A. Thorburn, H. L. Ford, Oncogene 2013, 32, 1341.
-
- H. Walczak, R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. L. Schuh, D. H. Lynch, Nat. Med. 1999, 5, 157.
-
- A. Ashkenazi, R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. Mcmurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R. H. Schwall, J. Clin. Invest. 1999, 104, 155.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous